Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Date:9/21/2007

NEW YORK, Sept. 21 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced the appointment of Michael P. Tarnok to the Company's Board of Directors.

Mr. Tarnok, 53, a seasoned finance and operational executive, joins the Keryx Board with extensive pharmaceutical industry experience in a wide range of functional areas. Mr. Tarnok spent the majority of his career at Pfizer Inc., which he joined in 1989 as Finance Director - US Manufacturing, and from 2000-2007, served as Senior Vice President, Finance in Pfizer's US Pharmaceuticals Division. In this position, Mr. Tarnok handled all finance responsibilities for the division, including Contracting, Trade management, forecasting of significant product launches and Sarbanes Oxley compliance. Prior to joining Pfizer, Mr. Tarnok worked primarily in financial disciplines for ITT Rayonier, Inc., Celanese Corporation and Olivetti Corporation of America. Mr. Tarnok earned an M.B.A. in Marketing from New York University and B.S. in Accounting from St. John's University.

"We are pleased that Mike has agreed to join the Keryx Board of Directors," stated Michael S. Weiss, Chairman and Chief Executive Officer of Keryx. Weiss continued, "Mike has extensive financial, operational and manufacturing experience in the pharmaceutical industry, and we are excited to have his broad experience in the boardroom as we plan for the launch of Sulonex(TM) and the transition from a development stage company into a commercial organization. Mike played a significant role in the rapid growth of Pfizer's U.S. Pharmaceutical division and his perspective and sense of scale will be invaluable as we continue to build Keryx into a leading biotechnology company."

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Mass. , March 22, 2017   iSpecimen ... today announced that Doctors Pathology Service (DPS), ... region of the United States , ... Delaware Health Information Network (DHIN) to make ... The novel program, announced in 2015 ...
(Date:3/22/2017)... 2017   VWR (NASDAQ: VWR), ... and service solutions to laboratory and production ... EPL Archives, Inc., an international biorepository services ... regulated product research, development and commercialization lifecycle ... ancillary services. EPL Archives is widely recognized ...
(Date:3/22/2017)... ... March 21, 2017 , ... ... more than tripling its goal and raising over $30,000 in the first 40 ... grows nutritious veggies & herbs fast, easy, and affordably, anywhere. , “Simply add ...
(Date:3/22/2017)... Iowa (PRWEB) , ... March 22, 2017 , ... March ... is time for another green revolution, one that utilizes technological innovation in smart, sustainable ... tangible aspects of life such as aesthetics and environmental stability. This paper is the ...
Breaking Biology Technology:
(Date:3/20/2017)... ALLENTOWN, Pa. , March 20, 2017 ... PD 2.0 personal spirometer and Wellness Management System (WMS), ... Founded in 2010, PMD Healthcare is a ... Company with a mission dedicated to creating innovative solutions ... of life. With that intent focus, PMD developed the ...
(Date:3/9/2017)... Australia , March 9, 2017 /PRNewswire/ ... at the prestigious World Lung Imaging Workshop at the ... Fouras , was invited to deliver the latest data ... This globally recognised event brings together leaders at the ... latest developments in lung imaging. "The ...
(Date:3/7/2017)... SALT LAKE CITY , March 7, 2017 /PRNewswire/ ... solutions that help top global companies identify the best ... Leonard as Chief Sales Officer (CSO) and ... and Kucer,s appointments round out a seasoned executive team poised ... year and beyond, building on a year of record ...
Breaking Biology News(10 mins):